CD86 Antibody

What is CD86 and why is it important in immunological research?

CD86 (B7-2) is a type I transmembrane protein primarily expressed on antigen-presenting cells (APCs), including B cells, dendritic cells, and macrophages. It functions as a co-stimulatory molecule alongside CD80 (B7-1) and serves as a ligand for CD28 and CTLA-4 receptors on T cells . CD86 plays a critical role in T-B cell crosstalk, T cell costimulation, and regulation of immune responses .

The importance of CD86 in research stems from its central role in:

• T cell proliferation and activation

• IL-2 production and immunoglobulin production

• Primary immune responses

• Potential as a therapeutic target and biomarker in various diseases

Understanding CD86 function through antibody-based research has significant implications for immunotherapy development, autoimmune disease treatments, and cancer immunology .

How do CD86 antibodies differ from other B7 family antibodies?

CD86 antibodies specifically target the B7-2 molecule, whereas other antibodies in the B7 family (such as anti-CD80 antibodies) target distinct but related co-stimulatory molecules. While both CD80 and CD86 bind to CD28 and CTLA-4, they exhibit different kinetics, expression patterns, and potentially distinct functions in immune responses .

Key differences include:

• CD86 is upregulated more rapidly upon stimulation compared to CD80, supporting its major contribution during the primary phase of immune responses

• CD86 and CD80 show differential expression on various cell types and under different activation conditions

• Domain depletion epitope mapping indicates that binding sites for CD86 antibodies like clone Bu63 are located within the Ig-v-like domain of CD86

• CD86 appears to play a role distinct from CD80 in T helper cell differentiation

These differences make CD86 antibodies valuable tools for specifically investigating this co-stimulatory pathway independent of other B7 family members.

What detection methods can be used with CD86 antibodies?

CD86 antibodies can be employed in various detection techniques depending on research requirements:

For optimal results, antibody titration is recommended for each specific application. For example, for Western blot applications, dilutions of 1:500-1:3000 have been reported as effective , while flow cytometry may require ≤0.125 μg per test for optimal staining .

How should CD86 antibodies be validated before experimental use?

Proper validation of CD86 antibodies is essential for reliable experimental results. A comprehensive validation approach should include:

Specificity testing:

• Use of positive and negative control cell lines (e.g., CD86-expressing Ramos cells versus CD86 knockout Ramos cells)

• Western blot analysis showing specific band at approximately 74-75 kDa

• Flow cytometric analysis comparing staining with isotype control antibodies

Functional validation:

• Verification of the antibody's ability to detect changes in CD86 expression following stimulation

• Confirmation of expected staining patterns on known CD86-expressing cells such as activated B cells, monocytes, and dendritic cells

• Testing the antibody's ability to block CD86-mediated functional responses, such as T cell activation or IL-2 secretion

Cross-reactivity assessment:

• Testing across relevant species if cross-reactivity is claimed

• Evaluation in the specific experimental system to be used

The validation data from R&D Systems demonstrates how CD86 antibody specificity can be confirmed using knockout cell lines, where a specific 74 kDa band is detected in parental Ramos cells but absent in CD86 knockout Ramos cells, with GAPDH serving as a loading control .

What are the optimal conditions for detecting CD86 expression by flow cytometry?

Flow cytometry is a widely used method for detecting CD86 expression on cell surfaces. Based on the research literature, the following protocol optimizations are recommended:

Sample preparation:

• For peripheral blood analysis: Isolate mononuclear cells using density gradient centrifugation

• For cell lines: Harvest during log phase growth and maintain viability >90%

• Use 1-5 × 10^5 cells per test for optimal resolution

Staining protocol:

• Block Fc receptors to minimize non-specific binding (10-15 minutes at room temperature)

• Apply CD86 primary antibody (e.g., clone BU63 or GL1 for mouse samples)

• For direct detection: Use fluorochrome-conjugated antibodies (e.g., PE-conjugated)

• For indirect detection: Follow with appropriate secondary antibody (e.g., PE-conjugated goat anti-mouse IgG)

• Include proper isotype controls to establish background staining levels

• For multi-color analysis: Include CD14 (for monocytes) or other relevant markers

Instrument settings:

• Optimize voltage settings using single-stained controls

• For PE-conjugated antibodies: Use 488-561 nm excitation and 578 nm emission detection

• Collect at least 10,000 events in the relevant gate for robust analysis

Data analysis:

• Gate on viable cells using appropriate viability dyes

• Further gate on relevant populations (monocytes, B cells, etc.)

• Report data as percent positive and/or mean/median fluorescence intensity

• Compare to isotype controls to determine specific staining

This approach has been validated in multiple studies, including detection of CD86 on human blood monocytes and Ramos lymphoma cell lines .

How can researchers troubleshoot inconsistent CD86 antibody staining?

Inconsistent staining with CD86 antibodies can result from various factors. Here is a systematic troubleshooting approach:

Sample-related issues:

• Cell viability: Poor viability (<90%) can cause increased non-specific binding. Ensure proper sample handling and include viability dyes.

• Activation status: CD86 expression is dynamically regulated. Standardize activation conditions and timing of cell collection.

• Receptor occupancy: Pre-existing ligand binding may block antibody epitopes. Consider acid washing to remove bound proteins.

Technical factors:

• Antibody titration: Sub-optimal antibody concentration leads to poor signal-to-noise ratio. Perform careful titration experiments (recommended ≤0.125 μg per test for flow cytometry) .

• Buffer composition: Sodium azide or certain fixatives may affect epitope recognition. Test different buffer conditions.

• Incubation conditions: Temperature and duration affect binding kinetics. Standardize these parameters across experiments.

Instrument and reagent variables:

• Lot-to-lot variation: Different antibody lots may have varying affinities. Include internal controls with each new lot.

• Fluorochrome stability: Photobleaching or degradation can reduce signal. Protect conjugated antibodies from light and follow storage recommendations.

• Instrument calibration: Fluctuations in laser power or detector settings impact fluorescence intensity. Use calibration beads regularly.

If inconsistent staining persists despite addressing these factors, consider using alternative antibody clones or detection methods. For example, if flow cytometry yields inconsistent results, Western blotting might provide more stable measurements of total CD86 expression levels .

How can CD86 antibodies be utilized to study T cell costimulation mechanisms?

CD86 antibodies serve as powerful tools for dissecting the complex mechanisms of T cell costimulation. Advanced research approaches include:

Functional blocking studies:

• Using anti-CD86 antibodies to selectively inhibit the CD86-CD28/CTLA-4 pathway while leaving CD80 interactions intact

• Measuring downstream effects on T cell proliferation, cytokine production, and effector functions

• Comparing with combined CD80/CD86 blockade to delineate unique contributions of each pathway

Studies have demonstrated that intraperitoneal injection of anti-CD86 antibody inhibited specific IgE antibody responses, highlighting the critical role of CD86 in triggering antigen-specific immune responses .

Co-culture systems:

• Establishing APC-T cell co-cultures with selective CD86 antibody blocking

• Using flow cytometry to simultaneously monitor CD86 expression, T cell activation markers, and intracellular signaling

• Implementing time-lapse imaging to visualize immunological synapse formation in the presence of CD86 blocking antibodies

Genetic complementation approaches:

• Combining CD86 knockout systems with rescue experiments using wild-type or mutated CD86

• Using antibodies to verify expression and proper localization of CD86 variants

• Correlating structural features of CD86 with functional outcomes using domain-specific antibodies

The differential binding of antibodies like clone Bu63 to the Ig-v-like domain can provide insights into structure-function relationships of CD86 in T cell costimulation .

What is the significance of CD86 as a predictive biomarker in immunotherapy response?

Recent research has identified CD86 expression as a potentially valuable predictive biomarker for immunotherapy response, particularly in the context of therapeutic vaccines and immune checkpoint inhibitors.

A post hoc analysis of clinical trials involving human papillomavirus vaccine (IGMKK16E7) demonstrated that:

• CD86 was the only predictive biomarker showing significant diagnostic performance with histological complete response (area under ROC curve = 0.71, 95% CI = 0.53 to 0.88, p = 0.020)

• Patients with complete response had significantly lower CD86 expression (CD86-low) than non-responders (p = 0.035)

• Complete response rates for CD86-low and CD86-high patients were 50% and 19%, respectively (p = 0.047)

• CD86-low patients showed a 1.5-fold increase in complete response rate compared to all patients

These findings suggest that:

• Pre-treatment assessment of CD86 expression using antibody-based methods could help stratify patients for immunotherapy trials

• The mechanism may involve differential regulation of costimulatory pathways in the tumor microenvironment

• CD86 expression patterns may influence the balance between effector and regulatory T cell responses

Interestingly, gene expression analysis revealed that CD86 and CTLA4 showed the strongest positive correlation in the incomplete response group (p < 0.001, r = 0.83), while this correlation was absent in complete responders . This suggests a complex interplay between costimulatory molecules that influences treatment outcomes.

How do CD86 expression patterns differ across immune cell subsets and disease states?

CD86 expression exhibits significant heterogeneity across immune cell populations and can be dramatically altered in various disease contexts. Understanding these patterns is crucial for interpreting experimental results and developing targeted therapies.

Cell type-specific expression patterns:

Disease-associated alterations:

• Upregulation in inflammatory conditions and autoimmune diseases

• Altered expression in tumor microenvironments, potentially correlating with immunotherapy response

• Dynamic changes during infection that may influence pathogen clearance versus persistence

Research has shown that lipopolysaccharide (LPS) can induce CD86 expression primarily on B cells. CD86+ cells appear in peritoneal cavities and spleens eight hours after LPS injection and remain detectable for approximately one week . These CD86+ cells are predominantly surface Ig-positive B-cells along with some Ig-negative cells, suggesting that LPS-induced CD86 expression may play an important role in antigen presentation and subsequent immune responses .

In the context of HPV vaccine response, gene expression correlation analyses revealed distinct patterns in responders versus non-responders:

• In complete responders: CD86 showed a negative correlation with CD80 (p = 0.019, r = -0.94) and no correlation with CTLA4

• In non-responders: CD86 strongly correlated with CTLA4 (p < 0.001, r = 0.83)

These differential expression patterns and correlations provide insights into the complex immunoregulatory networks in which CD86 participates and offer potential targets for therapeutic intervention.

How should researchers design experiments to assess CD86 blocking antibody efficacy?

Designing rigorous experiments to evaluate CD86 blocking antibody efficacy requires careful consideration of multiple factors:

In vitro experimental design:

• Antibody characterization:

  • Confirm binding specificity using CD86-positive and CD86-knockout cell lines

  • Determine effective blocking concentration through dose-response experiments

  • Evaluate potential Fc-mediated effects using F(ab')2 fragments as controls

• Functional assays:

  • Mixed lymphocyte reactions with CD86-expressing APCs and allogeneic T cells

  • Cytokine production assays (particularly IL-2) with quantification by ELISA or intracellular cytokine staining

  • Co-culture systems with CD86-expressing cells and responder T cells measuring proliferation via thymidine incorporation or CFSE dilution

• Controls:

  • Isotype-matched control antibodies

  • Anti-CD80 antibodies to distinguish pathway-specific effects

  • Combined CD80/CD86 blockade to assess redundancy

In vivo experimental approaches:

• Dosing optimization:

  • Pilot studies to determine effective antibody concentrations and dosing schedules

  • Pharmacokinetic analysis to confirm antibody persistence in relevant tissues

  • Assessment of target coverage using ex vivo analysis of CD86 occupancy

• Model selection:

  • Choose disease models with established CD86 dependency

  • Consider genetic backgrounds (wild-type vs. CD80-deficient) to isolate CD86-specific effects

  • Use models that recapitulate human disease mechanisms when possible

• Outcome measures:

  • Antigen-specific antibody responses, particularly IgE responses which have been shown to be inhibited by anti-CD86 antibody administration

  • T cell activation status in lymphoid organs

  • Disease-specific parameters (e.g., autoantibody levels, tumor growth)

Studies have demonstrated that intraperitoneal injection of anti-CD86 antibody can prevent the production of antigen-specific IgE antibody responses induced by stimuli like lipopolysaccharide , providing a model system for evaluating blocking efficacy.

What factors influence CD86 detection sensitivity across different immunoassay platforms?

Multiple factors can significantly impact CD86 detection sensitivity across various immunoassay platforms, requiring careful optimization for reliable results:

Antibody-related factors:

Sample preparation considerations:

• Fresh versus fixed samples: Fixation can mask epitopes but preserves morphology

• Buffer composition: Detergents, blockers, and stabilizers can influence antibody-antigen interactions

• Antigen retrieval methods: Critical for formalin-fixed samples in IHC applications

Platform-specific optimization:

• Flow cytometry:

  • Fluorochrome brightness (PE offers higher sensitivity than FITC)

  • Instrument settings (voltage optimization, compensation)

  • Signal amplification systems for low-abundance targets

• Western blot:

  • Reducing versus non-reducing conditions (CD86 is detected at ~75 kDa under reducing conditions)

  • Transfer efficiency optimization

  • Detection system sensitivity (chemiluminescence versus fluorescence)

• Immunohistochemistry/Immunofluorescence:

  • Antigen retrieval methods

  • Signal amplification (tyramide signal amplification, polymer-based detection)

  • Background reduction strategies

Detection thresholds vary significantly between methods, with flow cytometry generally offering the highest sensitivity for cell surface CD86 detection, while Western blot provides better specificity for confirming molecular weight and expression levels .

How can researchers integrate CD86 expression data with other immune parameters for comprehensive analysis?

Modern immunological research requires integrative approaches that combine CD86 expression data with other immune parameters to develop a comprehensive understanding of immune responses. Advanced strategies include:

Multi-parameter flow cytometry:

• Design panels that include CD86 alongside lineage markers, activation markers, and functional readouts

• Implement dimensionality reduction techniques (tSNE, UMAP) to visualize high-dimensional data

• Apply clustering algorithms to identify novel cell populations based on CD86 co-expression patterns

Correlation analyses with gene expression:
Research has demonstrated significant correlations between CD86 and other immune molecules that provide insight into functional relationships:

• CD86 shows strong positive correlation with CTLA4 in non-responders to immunotherapy (p < 0.001, r = 0.83)

• CD86 demonstrates negative correlation with CD8 in some contexts (p < 0.001, r = -0.53)

• In complete responders to HPV vaccine, CD86 shows negative correlation with CD80 (p = 0.019, r = -0.94)

These correlation patterns can reveal functional relationships and potential regulatory mechanisms.

Integrated analysis frameworks:

• Build comprehensive datasets combining:

  • CD86 protein expression (flow cytometry, IHC)

  • Transcriptomic data (bulk RNA-seq, single-cell RNA-seq)

  • Functional readouts (cytokine production, proliferation)

  • Clinical outcomes in patient studies

• Apply machine learning approaches to:

  • Identify patterns not apparent with conventional analysis

  • Build predictive models of treatment response

  • Discover novel biomarker combinations with superior predictive power

• Validate findings through:

  • In vitro functional studies with CD86 blocking/stimulation

  • In vivo models with genetic manipulation of CD86

  • Independent patient cohorts for clinical correlations

The research demonstrating CD86 as a predictive biomarker for HPV vaccine response exemplifies this approach, where ROC curve analysis (AUC = 0.71) established CD86 as a significant predictor within a comprehensive panel of immune markers .

How should researchers reconcile contradictory findings regarding CD86 function across different experimental systems?

Contradictory findings regarding CD86 function are common in the literature and require careful analysis. Researchers should consider several factors when reconciling these discrepancies:

Context-dependent effects:

• Cell type specificity: CD86 may function differently on B cells versus dendritic cells or macrophages

• Microenvironmental factors: Cytokine milieu can dramatically alter CD86 signaling outcomes

• Species differences: Mouse and human CD86 may have divergent functions in certain contexts

Methodological variables:

• Antibody clone selection: Different epitope targeting can yield different functional outcomes

• Genetic approaches versus antibody blocking: Complete absence (knockout) versus partial inhibition

• In vitro versus in vivo systems: Complex in vivo environments may reveal regulatory mechanisms absent in simplified in vitro systems

Integration strategies:

• Direct experimental comparison:

  • Replicate contradictory findings using identical protocols

  • Systematically vary one parameter at a time to identify critical variables

  • Employ multiple complementary techniques to assess the same biological question

• Meta-analysis approach:

  • Systematically review experimental conditions across contradictory studies

  • Identify patterns in experimental design that correlate with specific outcomes

  • Generate hypotheses about context-dependent regulation

• Mechanistic resolution:

  • Develop molecular models that can account for apparently contradictory results

  • Test models with targeted experiments examining signaling pathways

  • Consider temporal dynamics and feedback loops that may explain different outcomes at different timepoints

For example, while some studies suggest CD86 primarily promotes immune activation, others indicate regulatory roles in certain contexts. These apparently contradictory findings might be reconciled by considering the differential expression and correlation patterns observed in responders versus non-responders to HPV vaccine, where CD86 shows distinct correlation patterns with other immune molecules depending on the clinical outcome .

What are the most common pitfalls in CD86 antibody-based research and how can they be avoided?

CD86 antibody-based research presents several common pitfalls that can compromise experimental validity and reproducibility. Awareness of these challenges and implementation of appropriate controls can significantly improve research quality:

Technical pitfalls:

• Non-specific binding:

  • Issue: Fc receptor binding, particularly in macrophages and B cells

  • Solution: Use F(ab')2 fragments, include Fc receptor blocking reagents, and validate with isotype controls

  • Validation approach: Compare staining patterns in CD86-knockout systems

• Clone-dependent artifacts:

  • Issue: Different antibody clones may have varying effects on CD86 function

  • Solution: Confirm key findings with multiple antibody clones

  • Validation approach: Compare functional effects of different clones targeting distinct epitopes

• Inadequate controls:

  • Issue: Missing critical controls leads to misinterpretation

  • Solution: Always include isotype controls, biological negative controls (CD86-negative cells), and positive controls

  • Validation approach: Include CD86 knockout cell lines as definitive negative controls

Interpretational pitfalls:

• Correlation versus causation:

  • Issue: Attributing functional outcomes directly to CD86 based solely on correlation

  • Solution: Complement correlative studies with direct functional manipulation using blocking antibodies or genetic approaches

  • Validation approach: Perform CD86 blocking experiments in parallel with observational studies

• Overlooking compensatory mechanisms:

  • Issue: Failing to account for upregulation of alternative pathways when CD86 is blocked

  • Solution: Assess expression of related molecules (CD80) following CD86 manipulation

  • Validation approach: Combined blockade of multiple pathways to reveal functional redundancy

• Extrapolation beyond experimental context:

  • Issue: Generalizing findings from one experimental system to dissimilar contexts

  • Solution: Validate key findings across multiple model systems

  • Validation approach: Parallel studies in different cell types or species with appropriate controls

Western blot analyses from R&D Systems demonstrate proper validation approaches, showing that anti-CD86 antibody detects a specific band at approximately 74 kDa in parental Ramos cells but not in CD86 knockout Ramos cells, with GAPDH serving as a loading control .

How do CD86 expression patterns correlate with functional T cell responses in different disease contexts?

CD86 expression patterns show complex correlations with T cell responses across various disease contexts, providing insights into both pathogenesis and potential therapeutic interventions:

Infectious diseases:

• In acute infections, rapid upregulation of CD86 on APCs promotes protective T cell responses

• Certain pathogens can manipulate CD86 expression to evade immunity

• LPS-induced CD86 expression on B cells and other APCs appears within 8 hours of exposure and remains detectable for approximately one week, facilitating antigen-specific immune responses

Autoimmune disorders:

• Aberrant CD86 expression may contribute to loss of self-tolerance

• Blocking CD86 has shown therapeutic potential in some autoimmune models

• The balance between CD86 and inhibitory signals influences disease progression

Cancer immunotherapy:

Correlation with specific T cell functional outcomes:

Gene expression correlation analyses reveal mechanistic insights:

• In complete responders to HPV vaccine, CD86 shows negative correlation with CD80 (p = 0.019, r = -0.94) and no correlation with CTLA4

• In non-responders, CD86 strongly correlates with CTLA4 (p < 0.001, r = 0.83)

• These distinct correlation patterns suggest different immunoregulatory networks operating in responders versus non-responders

Understanding these context-specific relationships provides a foundation for developing more targeted therapeutic approaches and better predictive biomarkers for treatment response.